Glaxo launches OTC weight-loss drug alli in Europe

Mon Apr 20, 2009 12:59pm BST
 
Email | Print | | Single Page
[-] Text [+]

LONDON (Reuters) - GlaxoSmithKline (GSK.L) said on Monday it had launched its non-prescription weight-loss drug alli in pharmacies across Europe, boosting its line-up of consumer healthcare products.

The move had been expected after Glaxo, the world's second-biggest drugmaker, won final approval for the over-the-counter (OTC) medicine from European authorities in January.

Glaxo sees such OTC medicines as a growth opportunity at a time when sales of many prescription products are slowing.

Alli, a half-dose version of Roche's (ROG.VX) prescription drug Xenical, has been available without prescription in the United States since 2007. It works by reducing the amount of fat the body absorbs from food.

(Reporting by Ben Hirschler; Editing by David Holmes)

 
Detail showing a commercial U.S. Dollar rate against British Sterling is displayed in central London in this file photo December 1, 2006.  REUTERS/Toby Melville
Pound picking up strength

Sterling will gradually strengthen against the dollar over the next 12 months but is unlikely to move much, a Reuters poll shows.  Full Article | Related Story 

Market Update

  • UKUK
  • USUS
  • Europe
  • Asia
  • UK Most Actives

Most Popular Business News on Reuters UK

  • Articles
  • Videos